A detailed history of Jacobs Levy Equity Management, Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 129,011 shares of PTGX stock, worth $6.14 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
129,011
Previous 129,011 -0.0%
Holding current value
$6.14 Million
Previous $3.73 Million 19.77%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 16, 2023

SELL
$16.68 - $23.66 $291,499 - $413,482
-17,476 Reduced 11.93%
129,011 $2.15 Million
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $1.34 Million - $2.19 Million
-74,504 Reduced 33.71%
146,487 $4.05 Million
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $680,476 - $1.6 Million
-63,124 Reduced 22.22%
220,991 $5.08 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $219,144 - $332,586
29,775 Added 11.71%
284,115 $3.1 Million
Q3 2022

Nov 15, 2022

BUY
$7.86 - $11.71 $2 Million - $2.98 Million
254,340 New
254,340 $2.14 Million
Q3 2020

Nov 16, 2020

SELL
$15.19 - $22.4 $1.04 Million - $1.53 Million
-68,279 Closed
0 $0
Q2 2020

Aug 17, 2020

SELL
$6.19 - $18.84 $25,242 - $76,829
-4,078 Reduced 5.64%
68,279 $1.21 Million
Q1 2020

May 15, 2020

SELL
$5.4 - $9.22 $105,159 - $179,550
-19,474 Reduced 21.21%
72,357 $511,000
Q4 2019

Feb 14, 2020

BUY
$4.69 - $13.45 $365,918 - $1.05 Million
78,021 Added 564.96%
91,831 $647,000
Q3 2019

Nov 14, 2019

BUY
$9.41 - $16.56 $129,952 - $228,693
13,810 New
13,810 $166,000
Q2 2019

Aug 13, 2019

SELL
$8.98 - $12.96 $194,866 - $281,232
-21,700 Closed
0 $0
Q1 2019

May 14, 2019

SELL
$6.5 - $13.77 $43,550 - $92,259
-6,700 Reduced 23.59%
21,700 $273,000
Q4 2018

Feb 14, 2019

BUY
$6.3 - $10.44 $11,970 - $19,836
1,900 Added 7.17%
28,400 $191,000
Q3 2018

Nov 14, 2018

BUY
$6.82 - $11.26 $180,730 - $298,390
26,500 New
26,500 $273,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.